Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
353
Period ended Dec 31, 2025
Change on a year earlier
-0.8%
356 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 353 | -0.8% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 356 | -1.7% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 362 | -5.2% | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 382 | +36.4% | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 280 | -60.9% | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 716 | +13.7% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 630 | +87.5% | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
| FY2018 | Dec 31, 2018 | 336 | +6,620.0% | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
| FY2017 | Dec 31, 2017 | 5 | – | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
Breakdown
What makes up parsabiv (etelcalcetide — secondary hyperparathyroidism) — worldwide product sales ($m)
- Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — U.S. product sales ($M)192 · FY2025
- Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Rest of World (ROW) product sales ($M)161 · FY2025
- Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide reported sales growth YoY (%)-1.0% · FY2025
Cite this data
StockData. (2026). Amgen Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_parsabiv_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.